Serotonin Transporters in Obsessive-Compulsive-Related Disorders
NCT00082550 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30
Last updated 2017-07-02
Summary
This study will compare serotonin transporters in patients with obsessive-compulsive disorder (OCD) and healthy volunteers in order to better understand the role of serotonin in OCD. Serotonin is a chemical in the brain that transmits nerve impulses. The serotonin transporter (SERT) is a protein that regulates serotonin levels in the brain.
Normal, healthy volunteers and patients with OCD between 18 and 50 years of age and in overall good health may be eligible for this study. Candidates are screened with a medical history, physical examination, blood and urine tests, and a psychological interview and tests related to OCD symptoms. Participants undergo the following tests:
* Positron emission tomography (PET) scanning: For this test, subjects lie on the scanner bed, wearing special masks that are fitted to their heads and attached to the beds to help keep their heads still during the procedure. An 8-minute "transmission" scan is done to provide measures of the brain that will help calculate information obtained from subsequent scans. Then, a radioactive tracer is injected into a catheter (plastic tube) placed in the arm. The scan produces images of the serotonin transporters in the brain. Pictures are taken for about 2 hours, while the subject lies still on the scanner bed.
* Magnetic resonance imaging (MRI) scanning: An MRI scan of the brain is done within 1 year of the PET scan-that is, up to 1 year before or 1 year after the PET scan. MRI uses a magnetic field and radio waves to produce images of body tissues and organs. For this procedure, the patient lies on a table that is moved into the scanner (a narrow cylinder), wearing earplugs to muffle loud knocking and thumping sounds that occur during the scanning process. The procedure lasts about 1 hour, during which the patient will be asked to lie still for up to a few minutes at a time.
* Genotyping: Subjects provide a blood sample (4 tablespoons) for DNA testing to look for genes or gene regions that may contribute to serotonin activity. This may lead to a better understanding of the genetic underpinnings of the serotonin system that influence mood, movement, and addiction.
Conditions
- Obsessive-Compulsive Disorder
Sponsors & Collaborators
-
National Institute of Mental Health (NIMH)
lead NIH
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2004-05-10
- Completion
- 2007-04-09
Countries
- United States
Study Locations
More Related Trials
-
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
NCT00527579 ·Status: COMPLETED ·Phase: PHASE1
-
Use of [18F]FECNT in Positron Emission Tomography
NCT00083629 ·Status: COMPLETED ·Phase: PHASE1
-
Inhibitory Control of the Mind : Neural Bases and Impact for Obsessive-compulsive Disorders
NCT02850393 ·Status: UNKNOWN ·Phase: NA
-
Serotonin Receptors in Seizure Disorders
NCT00001932 ·Status: COMPLETED
-
Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a
NCT01461083 ·Status: COMPLETED ·Phase: PHASE1
-
Beyond Monoamines: The Role of the Nociceptin/Orphanin FQ Receptor in Major Depression
NCT05630963 ·Status: RECRUITING
-
Neuroimaging Studies of Reward Processing in Depression
NCT03026036 ·Status: COMPLETED
-
The Imaging Genetic Study of the Core Family of Obsessive-compulsive Disorder (OCD) Patient
NCT01298622 ·Status: UNKNOWN
-
Multicenter Comparative Study of the Activity of the Medial Prefrontal Cortex in Vulnerability to Depression
NCT02171923 ·Status: COMPLETED
-
Self Focus in Bipolar Disorder: A Functional Magnetic Resonance Imaging (fMRI) Study
NCT02253225 ·Status: COMPLETED
-
Development of Magnetic Resonance Spectroscopic Imaging Techniques for Imaging Metabolites in Human Brain and Muscle
NCT01266577 ·Status: RECRUITING ·Phase: NA
-
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
NCT05357612 ·Status: RECRUITING ·Phase: PHASE4
-
PET Neuroimaging of [11C]Mirtazapine
NCT00288782 ·Status: COMPLETED ·Phase: PHASE4
-
Improving Obsessive-compulsive Disorder Treatments: from Lesions to Neuromodulation Targets
NCT06490965 ·Status: RECRUITING ·Phase: NA
-
Investigating the Mechanisms of Mindfulness-based Cognitive Therapy (MBCT)
NCT02226042 ·Status: COMPLETED ·Phase: NA
-
Neural Correlates of Neurofeedback Training
NCT03165578 ·Status: UNKNOWN ·Phase: NA
-
SV2 PET Imaging With [11C]APP311
NCT03995121 ·Status: RECRUITING
-
Using Online Delivered Therapy and Brain Imaging to Better Understand OCD
NCT04630197 ·Status: COMPLETED ·Phase: NA
-
Study of Cognition and Control in Youths
NCT03393390 ·Status: COMPLETED
-
PET Brain and Whole Body Distribution Studies for Nociceptin/Orphanin FQ Peptide (NOP) Receptor Using [11C]NOP-1A
NCT01198197 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Predicting Treatment Outcomes in Refractory Constipation Through Brain Connectivity Evaluation
NCT06221722 ·Status: RECRUITING
-
fMRI Studies of Emotional Brain Circuitry in People With Major Depression
NCT00749125 ·Status: COMPLETED ·Phase: NA
-
Neural Mechanisms of Meditation Training in Healthy and Depressed Adolescents: An MRI Connectome Study
NCT04254796 ·Status: COMPLETED ·Phase: NA
-
Understanding Brain Reward Responses in Individuals With Major Depressive Disorder
NCT00183755 ·Status: COMPLETED
-
A Multimodal Neuroimaging Study of Brain Activation Patterns Under Ketamine
NCT03609190 ·Status: COMPLETED ·Phase: EARLY_PHASE1